Guggenheim Capital LLC grew its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 36.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 660,167 shares of the company’s stock after purchasing an additional 175,118 shares during the quarter. Guggenheim Capital LLC owned approximately 0.42% of Henry Schein worth $46,134,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Baker Avenue Asset Management LP purchased a new stake in Henry Schein in the 4th quarter worth $922,000. Deutsche Bank AG increased its holdings in Henry Schein by 300.6% in the 4th quarter. Deutsche Bank AG now owns 1,560,951 shares of the company’s stock worth $109,076,000 after acquiring an additional 1,171,302 shares in the last quarter. Jefferies Group LLC increased its holdings in Henry Schein by 89.0% in the 4th quarter. Jefferies Group LLC now owns 85,196 shares of the company’s stock worth $5,953,000 after acquiring an additional 40,109 shares in the last quarter. Advisor Group Inc. increased its holdings in Henry Schein by 42.4% in the 4th quarter. Advisor Group Inc. now owns 6,837 shares of the company’s stock worth $478,000 after acquiring an additional 2,036 shares in the last quarter. Finally, Generation Investment Management LLP increased its holdings in Henry Schein by 561.1% in the 4th quarter. Generation Investment Management LLP now owns 11,026,174 shares of the company’s stock worth $770,509,000 after acquiring an additional 9,358,345 shares in the last quarter. 98.57% of the stock is owned by hedge funds and other institutional investors.
Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at $68.05 on Friday. Henry Schein, Inc. has a one year low of $62.56 and a one year high of $93.50. The company has a current ratio of 1.45, a quick ratio of 0.76 and a debt-to-equity ratio of 0.32. The stock has a market cap of $10,458.88, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 1.67 and a beta of 1.09.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 20th. The company reported $0.97 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.97. Henry Schein had a net margin of 3.26% and a return on equity of 19.70%. The company had revenue of $3.32 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the previous year, the company posted $0.94 EPS. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. sell-side analysts forecast that Henry Schein, Inc. will post 4.08 earnings per share for the current year.
Several brokerages recently commented on HSIC. Stephens began coverage on shares of Henry Schein in a report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 price target for the company. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $77.00 price target (down previously from $79.00) on shares of Henry Schein in a report on Thursday, February 15th. Leerink Swann reissued a “hold” rating on shares of Henry Schein in a report on Tuesday, February 13th. Credit Suisse Group reissued a “neutral” rating and issued a $80.00 price target (down previously from $87.50) on shares of Henry Schein in a report on Tuesday, November 28th. Finally, Barclays began coverage on shares of Henry Schein in a report on Thursday, March 8th. They issued an “equal weight” rating and a $71.00 price target for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. Henry Schein has a consensus rating of “Hold” and a consensus target price of $82.31.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.